Related Experiment Video
Updated: Jul 14, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
AM-7359--a novel oxazolidinone with low resistance potential and potent activity against drug resistant pathogens
1Infectious Disease, Merck Research Laboratories, Rahway, New Jersey 07065, USA. karen_oberbye@merck.com
Abstract:
AM-7359 is a member of a novel series of oxazolidinones with antimicrobial activity against pathogens resistant to multiple antibiotics. Potent antibiotics with limited drug cross resistance to current therapeutic agents are needed for the treatment of drug resistant pathogens. This study investigated the resistance development to linezolid (LZD) and AM-7359 by key pathogens and the degree of cross resistance between these two oxazolidinones. Both AM-7359 and LZD, demonstrates a low frequency of resistance development. After 30 passages and selection for resistant development of four different Staphylococcus aureus and Enterococus faecium strains the minimum inhibitory concentration (MIC) for AM-7359 was 1
Related Concept Videos
Development of Antibiotic Resistance
Antimicrobial Effectiveness
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Bacterial DNA Synthesis
Clinical Significance of Antibiotic Resistance
Antibiotic Selection

